Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBITO: Personalized Therapy in High-risk BRCA1-like Breast Cancer
NCT02810743Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2017
- Primary completion
- Jul 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin, cyclophosphamide, carboplatin, Paclitaxel Micelles for Injection, olaparib in breast cancer, sponsored by Netherlands Cancer Institute. Started Jan 2017; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicincyclophosphamidecarboplatinPaclitaxel Micelles for Injectionolaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02810743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810743.